“More than a year after the Food and Drug Administration announced it had strengthened its drug safety system, the agency still lacks a reliable system for keeping track of emerging problems, congressional investigators concluded in a report to be released today.” [Los Angeles Times, below]
A front page report in The New York Times provides additonal information about the catastrophic TGN1412 medical experiment in which 6 previously healthy volunteers were intravenously injected with monoclonal antibody in a highly risky procedure.
An OpEd in The New York Times (below) is trumpeting psychiatry’s latest “cure” for depression: it requires surgical implantation of electrodes in the brain, continued “maintenance” with powerful psychotropic drugs, and it costs $40,000.
Unless Congress acts to overrule the FDA, research disasters such as occurred in London, when six healthy men were exposed to an experimental substance that brought them close to death, are likely to occur with increased frequency.
In a blistering letter addressed to the Secretary of Health and Human Services, Senator Grassley calls upon Michael Leavitt to give “immediate attention” to the serious issues raised by a Northfield Laboratory, non-consensual artificial blood experiment.
This controversial, commercial experiment is being conducted without informed consent in trauma patients who require blood to survive. PolyHeme is being tested in patients in ambulances and at hospital emergency facilities where these trauma patients are denied life-saving real blood.
The Wall Street Journal reports: “The FDA is allowing Northfield [Laboratories, Inc] to test its blood substitute without the consent of the trauma patients, who often are unconscious.”
Children have been dying from exposure to psychostimulant drugs as the FDA looked the other way:
“Science has become so severely politicized that one has to be skeptical of nearly every research result that is reported.”
The Senate Finance committee is cracking down on drug industry "educational grants" to physicians, medical associations and "patient advocacy" groups.
In its continuing coverage of corrupt clinical drug trial practices, Bloomberg News reports that all three founders of SFBC International, one of the largest clinical trial business operations that had failed to even screen human subjects for turberculosis, and threatened others with deportation if they refused to become guinea pigs, quit after the Senate Finance committee began investigating drug trial safety issues:
Bloomberg News published an update to its sensational special report: Big Pharma’s Shameful Secret
see: https://ahrp.org/infomail/05/11/03.php
